Literature DB >> 29455359

Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma?

Sandy R Durrani1,2,3, Vincent A Mukkada4,5, Theresa W Guilbert6,4.   

Abstract

Eosinophilic esophagitis and asthma are frequently found as comorbid conditions in children and adults along with other manifestations of atopic diathesis. These two conditions have similar T helper 2 responses-driven pathophysiology and share common management strategies such as using systemic corticosteroids and targeted anti-cytokine biologic therapies. Review of the literature finds that asthma is often a comorbid condition in eosinophilic esophagitis in both children and adults; however, the EoE-asthma relationship remains poorly characterized mechanistically and clinically. EoE and asthma commonly share several comorbid conditions such as allergic rhinitis and gastroesophageal reflux disease; therefore, addressing these comorbid conditions has the potential to improve and/or maintain control in both diseases. Similar to asthma, patients with EoE frequently demonstrate elevations in serum markers of atopy, including serum IgE levels, peripheral eosinophil counts, and T helper 2-related cytokines. Gastroesophageal reflux disease is thought to affect asthma through microaspirations, airway hyperresponsiveness, and increased vagal tone. The understanding of the relationship between gastroesophageal reflux and EoE is still evolving but seems to be bidirectional and interactive. In terms of treatment, similar classes of medications have been used in both EoE and asthma. In both children and adults, EoE remission can be achieved by food trigger avoidance and use of corticosteroids and biologic therapies. Asthma control is mostly achieved through inhaled corticosteroids, and long but biologic therapies are increasingly used in severe subsets of the disease. Significant clinical and mechanistic work needs to be accomplished to better understand the relationship between asthma, EoE, and their interaction with other allergic diseases. Understanding whether shared mechanisms exist can lead to the development of new diagnostic and therapeutic strategies. The following review examines the existing literature regarding prevalence, common comorbidities, and potential therapeutic approach and identifies gaps in knowledge and future directions.

Entities:  

Keywords:  Asthma; Diagnosis; Eosinophilic esophagitis; Gastroesophageal reflux disease; Prevalence; Treatment

Mesh:

Substances:

Year:  2018        PMID: 29455359      PMCID: PMC8048773          DOI: 10.1007/s12016-018-8670-7

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  78 in total

1.  Increased prevalence of airway reactivity in children with eosinophilic esophagitis.

Authors:  Nadia L Krupp; Sarita Sehra; James E Slaven; Mark H Kaplan; Sandeep Gupta; Robert S Tepper
Journal:  Pediatr Pulmonol       Date:  2015-10-28

2.  Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids.

Authors:  C A Liacouras; W J Wenner; K Brown; E Ruchelli
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-04       Impact factor: 2.839

3.  Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.

Authors:  Evan S Dellon; David A Katzka; Margaret H Collins; Mohamed Hamdani; Sandeep K Gupta; Ikuo Hirano
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

4.  Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.

Authors:  Toni O Kiljander; Susan M Harding; Stephen K Field; Mark R Stein; Harold S Nelson; Jan Ekelund; Marta Illueca; Ola Beckman; Mark B Sostek
Journal:  Am J Respir Crit Care Med       Date:  2005-12-15       Impact factor: 21.405

5.  Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis.

Authors:  Wael N Sayej; Raza Patel; Robert D Baker; Eduardo Tron; Susan S Baker
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-10       Impact factor: 2.839

Review 6.  Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.

Authors:  Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2007-08-08       Impact factor: 22.682

7.  Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids.

Authors:  Jessica Rajan; Robert O Newbury; Arjun Anilkumar; Ranjan Dohil; David H Broide; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2015-07-30       Impact factor: 10.793

Review 8.  Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis.

Authors:  Javier Molina-Infante; Bram D van Rhijn
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-07-08       Impact factor: 3.043

9.  Therapeutic options for severe asthma.

Authors:  Jilcy Mathew; Wilbert S Aronow; Dipak Chandy
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

Review 10.  Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis.

Authors:  Yoon Kong Loke; Patricia Blanco; Menaka Thavarajah; Andrew M Wilson
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

View more
  2 in total

Review 1.  Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.

Authors:  Sankei Nishima; Masanari Kozawa; Ki Lee Milligan; Nikolaos G Papadopoulos
Journal:  Asia Pac Allergy       Date:  2019-01-22

2.  Risk of fractures in individuals with eosinophilic esophagitis: nationwide population-based cohort study.

Authors:  John J Garber; Bjorn Roelstraete; Paul J Lochhead; Amiko M Uchida; Karl Michaëlsson; Ola Olén; Jonas F Ludvigsson
Journal:  Esophagus       Date:  2022-06-28       Impact factor: 3.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.